EP1377312A4 - Anthrax-letalfaktor hemmt tumorwachstum und angiogenese - Google Patents

Anthrax-letalfaktor hemmt tumorwachstum und angiogenese

Info

Publication number
EP1377312A4
EP1377312A4 EP02725277A EP02725277A EP1377312A4 EP 1377312 A4 EP1377312 A4 EP 1377312A4 EP 02725277 A EP02725277 A EP 02725277A EP 02725277 A EP02725277 A EP 02725277A EP 1377312 A4 EP1377312 A4 EP 1377312A4
Authority
EP
European Patent Office
Prior art keywords
angiogenesis
tumor growth
inhibits tumor
lethal factor
anthrax lethal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02725277A
Other languages
English (en)
French (fr)
Other versions
EP1377312A1 (de
Inventor
Nicholas S Duesbery
Craig P Webb
Woude George F Vande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VAN ANDEL INSTITUTE
ANDEL INST VAN
Original Assignee
VAN ANDEL INSTITUTE
ANDEL INST VAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VAN ANDEL INSTITUTE, ANDEL INST VAN filed Critical VAN ANDEL INSTITUTE
Publication of EP1377312A1 publication Critical patent/EP1377312A1/de
Publication of EP1377312A4 publication Critical patent/EP1377312A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
EP02725277A 2001-03-22 2002-03-22 Anthrax-letalfaktor hemmt tumorwachstum und angiogenese Withdrawn EP1377312A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27762501P 2001-03-22 2001-03-22
US277625P 2001-03-22
PCT/US2002/008656 WO2002076496A1 (en) 2001-03-22 2002-03-22 Anthrax lethal factor inhibits tumor growth and angiogenesis

Publications (2)

Publication Number Publication Date
EP1377312A1 EP1377312A1 (de) 2004-01-07
EP1377312A4 true EP1377312A4 (de) 2004-10-06

Family

ID=23061685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02725277A Withdrawn EP1377312A4 (de) 2001-03-22 2002-03-22 Anthrax-letalfaktor hemmt tumorwachstum und angiogenese

Country Status (4)

Country Link
EP (1) EP1377312A4 (de)
AU (1) AU2002255852B2 (de)
CA (1) CA2442015A1 (de)
WO (1) WO2002076496A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2419567A1 (en) 2000-09-01 2002-03-07 George Vande Woude Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
WO2004100978A1 (en) * 2003-05-13 2004-11-25 Medvet Science Pty. Ltd. A method of modulating cellular transmigration and agents for use therein
ATE451115T1 (de) * 2003-07-07 2009-12-15 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
NZ546011A (en) 2003-10-21 2009-09-25 Warner Lambert Co Polymorphic form of N-[(R)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
AT504159A1 (de) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc Verwendung von proteasen
WO2009132397A1 (en) * 2008-05-01 2009-11-05 University Of South Australia Methods and agents for modulating the level and/or activity of hif-2 alpha protein
WO2012149547A1 (en) * 2011-04-28 2012-11-01 Duke University Methods of treating hemoglobinopathies
WO2013082511A1 (en) * 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2014081760A1 (en) 2012-11-20 2014-05-30 Duke University Methods of treating hemoglobinopathies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
GB2323845A (en) * 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
WO1999001426A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6485925B1 (en) * 1998-04-01 2002-11-26 The United States Of America As Represented By The Department Of Health And Human Services Anthrax lethal factor is a MAPK kinase protease
ATE310567T1 (de) * 1998-12-22 2005-12-15 Warner Lambert Co Chemotheriapie mit einem antimitotischen mittel und einem mek inhibitor
CN1149204C (zh) * 1999-01-13 2004-05-12 沃尼尔·朗伯公司 1-杂环取代的二芳基胺
JP2002534497A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー スルホヒドロキサム酸およびスルホヒドロキサメートおよびｍｅｋ阻害剤としてのその使用
EP1163215A1 (de) * 1999-03-19 2001-12-19 Du Pont Pharmaceuticals Company Amino-thio-acrylonitrile als mek-inhibitoren
WO2000056725A1 (en) * 1999-03-19 2000-09-28 Du Pont Pharmaceuticals Company N-adamant-1-yl-n'-[4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
GB9910580D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 306a, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2000 (2000-11-16), BONATI ANTONIO ET AL: "Selective inhibition of MEK1 kinase downmodulates ERK activity and proliferation of AML blasts", XP002279051, Database accession no. PREV200100301863 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10-01), PRICE DAVID T ET AL: "Activation of extracellular signal-regulated kinase in human prostate cancer", XP002279050, Database accession no. PREV199900481092 *
JOURNAL OF UROLOGY, vol. 162, no. 4, October 1999 (1999-10-01), pages 1537 - 1542, ISSN: 0022-5347 *
See also references of WO02076496A1 *

Also Published As

Publication number Publication date
WO2002076496A1 (en) 2002-10-03
AU2002255852B2 (en) 2006-11-09
EP1377312A1 (de) 2004-01-07
CA2442015A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
AU2002352903A8 (en) Mesoporous materials and methods
AU2002342653A8 (en) Modified growth hormone
PT2311466E (pt) Compostos antimicrobianos e métodos para a sua utilização
EP1377312A4 (de) Anthrax-letalfaktor hemmt tumorwachstum und angiogenese
IL154553A0 (en) Urocortin-iii and uses thereof
EP1478228A4 (de) Antimikrobielle systeme und verfahren
GB0128301D0 (en) Adustable beds or recliners
GB0124735D0 (en) Bedding improvements
HK1050613A1 (en) Poultry feed and the use thereof
GB0126889D0 (en) Compounds and their uses
EP1392317A4 (de) Substituierte 1-benzazepine und derivative davon
HUP0402334A3 (en) Modified human growth hormone
IL160532A0 (en) Fungicidal composition comprising pyrimethanil and iprodione
GB0106565D0 (en) Growth hormone treatment
IL146694A0 (en) Biologically active complex
AU147483S (en) Mailbox
EP1367123A4 (de) Neurotonin und dessen verwendung
EP1367333A4 (de) Wärmepumpe und entfeuchter
GB0116498D0 (en) Patio eater
GB0200843D0 (en) Benzodioxinopyrroles their preparation and use
CA98106S (en) Castor
HUP0401193A3 (en) Fungicidal 1-benzoxepin derivatives and preparation thereof
GB0130025D0 (en) Headboard
TW516367U (en) Structure improvement of double-layered water-storage-type flowerpot

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031007

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040823

17Q First examination report despatched

Effective date: 20080320

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091001